Maravai LifeSciences (MRVI) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $65.2 million, with adjusted EBITDA of $12.7 million and an adjusted EPS loss of $0.02.

• Net loss for Q3 2024 was $176 million, including a $154.2 million non-cash goodwill impairment.

• Results were below expectations due to customer program delays, muted demand in Nucleic Acid Production, and global biologics market softness.

• The company is advancing innovation, launching new products, and expanding capabilities through the pending Officinae Bio acquisition.

• Cash and cash equivalents stood at $578 million at quarter-end.

Financial highlights

• Q3 2024 revenue: $65.2 million, down 2.5% year-over-year; adjusted EBITDA: $12.7 million (19.5% margin).

• GAAP net loss: $176 million, including a $154.2 million goodwill impairment; adjusted EPS: -$0.02; GAAP EPS: -$0.70.

• Gross margin for Q3 2024 was 43.5%, down from 45.1% in Q3 2023.

• Year-to-date adjusted EBITDA: $37.5 million.

• Net cash position of $49 million at quarter-end, with $529 million in gross debt.

Outlook and guidance

• 2024 revenue guidance lowered to $255–$265 million, a 5% reduction at midpoint.

• Adjusted EBITDA margin for 2024 now expected at 16–18%.

• Q4 revenue expected between $52–$62 million; NAP at $43 million midpoint, BST at $14 million.

• Guidance excludes impact from the pending Officinae Bio acquisition, expected to close early 2025.

• Capital expenditures for 2024 projected at $30 million.